Document is current
Any future updates will be listed below
-
Authors
Vu, Hoang Minh Chau https://orcid.org/0009-0001-7861-098X
Kayano, Daiki
Wakabayashi, Hiroshi
Kuroda, Rie
Kinuya, Seigo
-
Funding
Funding for this research was provided by:
Kanazawa University
- License Information
-
More Information
Article History
Received: 22 September 2025
Accepted: 19 December 2025
First Online: 13 January 2026
Declarations
:
: Hiroshi Wakabayashi has received research funding from PDR Pharmaceutical Inc., the current marketer of the drug discussed in this manuscript. Seigo Kinuya has received research support from PDR Pharmaceutical Inc. during the development of ¹³¹I-MIBG for neuroblastoma.
: During the preparation of this work, the authors used Grammarly to improve the language and readability. After using this service, the authors reviewed and revised the content as necessary and take full responsibility for the final content of the publication.
